DLBCL

The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for mosunetuzumab (Lunsumio VELO) in combination with polatuzumab vedotin (Polivy) for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), who have received at least one prior systemic therapy. The […]

New Phase 3 frontMIND data to be presented at ASCO 2026 spotlight tafasitamab plus lenalidomide and R-CHOP in newly diagnosed high-risk DLBCL. The pivotal trial evaluates a frontline CD19-targeted immunotherapy strategy, with Incyte indicating the findings support future regulatory submissions.

ctDNA detection after LBCL therapy predicts 97% vs 29% progression-free survival, superior to PET scans for determining true remission status.

40% reduction in death risk with Pola-R-GemOx vs R-GemOx alone in relapsed/refractory DLBCL (HR 0.60, P=.0017) – POLARGO trial results.